JP2001511002A - Ts10q23.3と称する腫瘍抑制因子 - Google Patents

Ts10q23.3と称する腫瘍抑制因子

Info

Publication number
JP2001511002A
JP2001511002A JP53289798A JP53289798A JP2001511002A JP 2001511002 A JP2001511002 A JP 2001511002A JP 53289798 A JP53289798 A JP 53289798A JP 53289798 A JP53289798 A JP 53289798A JP 2001511002 A JP2001511002 A JP 2001511002A
Authority
JP
Japan
Prior art keywords
tissue
nucleic acid
cells
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP53289798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001511002A5 (cg-RX-API-DMAC7.html
Inventor
ステック,ピーター
パーズハウス,マーク・エイ
ジャサー,サーマー・エイ
ヤング,ダブリュー・ケイ・アルフレッド
タブティジャン,ショーン・ブイ
Original Assignee
ボード・オブ・リージェンツ・ザ・ユニバーシティ・オブ・テキサス・システム
ミリアド・ジェネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2001511002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ボード・オブ・リージェンツ・ザ・ユニバーシティ・オブ・テキサス・システム, ミリアド・ジェネティックス・インコーポレイテッド filed Critical ボード・オブ・リージェンツ・ザ・ユニバーシティ・オブ・テキサス・システム
Publication of JP2001511002A publication Critical patent/JP2001511002A/ja
Publication of JP2001511002A5 publication Critical patent/JP2001511002A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP53289798A 1997-01-30 1998-01-08 Ts10q23.3と称する腫瘍抑制因子 Withdrawn JP2001511002A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/791,115 1997-01-30
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3
PCT/US1998/000353 WO1998033907A1 (en) 1997-01-30 1998-01-08 A tumor suppressor designated ts10q23.3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008184139A Division JP4768783B2 (ja) 1997-01-30 2008-07-15 Ts10q23.3と称する腫瘍抑制因子

Publications (2)

Publication Number Publication Date
JP2001511002A true JP2001511002A (ja) 2001-08-07
JP2001511002A5 JP2001511002A5 (cg-RX-API-DMAC7.html) 2005-09-08

Family

ID=25152739

Family Applications (5)

Application Number Title Priority Date Filing Date
JP53289798A Withdrawn JP2001511002A (ja) 1997-01-30 1998-01-08 Ts10q23.3と称する腫瘍抑制因子
JP2008184139A Expired - Lifetime JP4768783B2 (ja) 1997-01-30 2008-07-15 Ts10q23.3と称する腫瘍抑制因子
JP2010139230A Expired - Lifetime JP5202583B2 (ja) 1997-01-30 2010-06-18 Ts10q23.3と称する腫瘍抑制因子
JP2013006918A Withdrawn JP2013128485A (ja) 1997-01-30 2013-01-18 Ts10q23.3と称する腫瘍抑制因子
JP2014040353A Withdrawn JP2014155493A (ja) 1997-01-30 2014-03-03 Ts10q23.3と称する腫瘍抑制因子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008184139A Expired - Lifetime JP4768783B2 (ja) 1997-01-30 2008-07-15 Ts10q23.3と称する腫瘍抑制因子
JP2010139230A Expired - Lifetime JP5202583B2 (ja) 1997-01-30 2010-06-18 Ts10q23.3と称する腫瘍抑制因子
JP2013006918A Withdrawn JP2013128485A (ja) 1997-01-30 2013-01-18 Ts10q23.3と称する腫瘍抑制因子
JP2014040353A Withdrawn JP2014155493A (ja) 1997-01-30 2014-03-03 Ts10q23.3と称する腫瘍抑制因子

Country Status (14)

Country Link
US (1) US6262242B1 (cg-RX-API-DMAC7.html)
EP (2) EP0972024B2 (cg-RX-API-DMAC7.html)
JP (5) JP2001511002A (cg-RX-API-DMAC7.html)
AR (1) AR011607A1 (cg-RX-API-DMAC7.html)
AT (1) ATE499444T1 (cg-RX-API-DMAC7.html)
AU (1) AU745296B2 (cg-RX-API-DMAC7.html)
CA (1) CA2278849C (cg-RX-API-DMAC7.html)
DE (1) DE69842141D1 (cg-RX-API-DMAC7.html)
DK (1) DK0972024T4 (cg-RX-API-DMAC7.html)
ES (1) ES2361044T5 (cg-RX-API-DMAC7.html)
IL (1) IL131168A0 (cg-RX-API-DMAC7.html)
PT (1) PT972024E (cg-RX-API-DMAC7.html)
WO (1) WO1998033907A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98756B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1756137A4 (en) * 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
BR122015032159A2 (pt) 2011-12-30 2019-08-27 Abbott Molecular Inc. método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
JP2000500329A (ja) 1995-10-23 2000-01-18 インペリアル キャンサー リサーチ テクノロジィ リミテッド 癌罹病性の診断およびその治療
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
WO1998033907A1 (en) 1998-08-06
ES2361044T5 (es) 2014-10-01
JP2010259438A (ja) 2010-11-18
JP4768783B2 (ja) 2011-09-07
CA2278849C (en) 2016-04-19
EP0972024B1 (en) 2011-02-23
AU6018998A (en) 1998-08-25
CA2278849A1 (en) 1998-08-06
ES2361044T3 (es) 2011-06-13
DK0972024T4 (da) 2014-07-07
AU745296B2 (en) 2002-03-21
ATE499444T1 (de) 2011-03-15
EP0972024A1 (en) 2000-01-19
US6262242B1 (en) 2001-07-17
ZA98756B (en) 1998-08-25
DK0972024T3 (da) 2011-04-26
DE69842141D1 (de) 2011-04-07
JP5202583B2 (ja) 2013-06-05
EP2366712A2 (en) 2011-09-21
EP2366712A3 (en) 2012-11-14
JP2014155493A (ja) 2014-08-28
JP2013128485A (ja) 2013-07-04
JP2009039107A (ja) 2009-02-26
PT972024E (pt) 2011-05-05
AR011607A1 (es) 2000-08-30
IL131168A0 (en) 2001-01-28
EP0972024B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
JP5202583B2 (ja) Ts10q23.3と称する腫瘍抑制因子
US8735066B2 (en) Tumor suppressor designated TS10Q23.3
JP4454670B2 (ja) Ts10q23.3と称する腫瘍抑制因子
JP2002502227A (ja) 乳癌および卵巣癌の素因の診断方法
JP2001522229A (ja) 抗酸化剤タンパク質2、遺伝子及びそれらの使用方法
JP2001517954A (ja) Noey2遺伝子組成物およびその使用方法
JP2004510408A (ja) 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法
JPH10505742A (ja) 17q−連鎖乳癌および卵巣癌感受性遺伝子
KR20020013477A (ko) 염색체 17p 연관된 전립선암 감수성 유전자
MXPA99007147A (en) A tumor suppressor designated ts10q23.3
WO2002048354A1 (en) Tumour suppressor gene identified on chromosome 18

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080307

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080428

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080428

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100216

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100616